Control of cardiac hypertrophy and heart failure by histone acetylation/deacetylation

Eric N Olson1, Johannes Backs, Timothy A McKinsey

  • 1Myogen, Inc., 757 W. 103rd Ave., Westminster, CO 80021, USA.

Novartis Foundation Symposium
|October 6, 2006
PubMed

Insights

Histone deacetylases (HDACs) control pathological cardiac growth. Disrupting HDACs in mice caused enlarged hearts, highlighting HDACs as therapeutic targets for heart failure.

Area of Science:

  • Cardiovascular Biology
  • Molecular Cardiology
  • Gene Regulation

Background:

  • Adult heart remodels under stress, leading to hypertrophy, failure, and death.
  • Pathological cardiac remodeling involves reactivation of fetal gene programs, impairing function.
  • Histone deacetylases (HDACs) are implicated in controlling pathological cardiac growth.

Purpose of the Study:

  • Investigate the role of Class II HDACs in cardiac response to stress.
  • Determine the impact of HDAC function on pathological cardiac remodeling and gene expression.
  • Explore therapeutic strategies targeting HDACs for heart failure.

Main Methods:

  • Utilized HDAC knockout mouse models.
  • Analyzed cardiac response to various pathological stress stimuli.
  • Examined gene expression related to cardiac growth and MEF2 signaling.

Main Results:

  • HDAC knockout mice exhibited hypersensitivity to stress signaling.
  • These mice developed significantly enlarged hearts under pathological stress.
  • Inability to counteract pathological MEF2 signaling was observed in knockout mice.

Conclusions:

  • Class II HDACs are crucial for maintaining normal cardiac size and function.
  • Dysregulation of HDACs promotes pathological cardiac hypertrophy and failure.
  • Modulating HDAC phosphorylation and function offers a potential therapeutic avenue for heart failure.

Related Concept Videos

Histone Modification02:32

Histone Modification

The histone proteins have a flexible N-terminal tail extending out from the nucleosome. These histone tails are often subjected to post-translational modifications such as acetylation, methylation, phosphorylation, and ubiquitination. Particular combinations of these modifications form “histone codes” that influence the chromatin folding and tissue-specific gene expression.
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone deacetylase,...
Histone Modification02:32

Histone Modification

The histone proteins have a flexible N-terminal tail extending out from the nucleosome. These histone tails are often subjected to post-translational modifications such as acetylation, methylation, phosphorylation, and ubiquitination. Particular combinations of these modifications form “histone codes” that influence the chromatin folding and tissue-specific gene expression.
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone deacetylase,...
Spreading of Chromatin Modifications02:25

Spreading of Chromatin Modifications

The histone proteins in the nucleosomes are post-translationally modified (PTM) to increase or decrease access to DNA. The commonly observed PTMs are methylation, acetylation, phosphorylation, and ubiquitination of lysine amino acids in the histone H3 tail region. These histone modifications have specific meaning for the cell. Hence, they are called "histone code". The protein complex involved in histone modification is termed as "reader-writer" complex.
Writers
The writer is an enzyme that can...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...